Pertussis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 99 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pertussis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pertussis - Pipeline Review, H1 2015', provides an overview of the Pertussis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pertussis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pertussis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pertussis Overview 10
Therapeutics Development 11
Pipeline Products for Pertussis - Overview 11
Pipeline Products for Pertussis - Comparative Analysis 12
Pertussis - Therapeutics under Development by Companies 13
Pertussis - Therapeutics under Investigation by Universities/Institutes 16
Pertussis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Pertussis - Products under Development by Companies 21
Pertussis - Products under Investigation by Universities/Institutes 23
Pertussis - Companies Involved in Therapeutics Development 24
Beijing Minhai Biotechnology Co., Ltd 24
Beijing Tiantan Biological Products Co., Ltd. 25
Bharat Biotech International Limited 26
Biological E. Limited 27
Daiichi Sankyo Company, Limited 28
DBV Technologies S.A. 29
Green Cross Corporation 30
Indian Immunologicals Limited 31
LG Life Sciences, Ltd. 32
NanoBio Corporation 33
Novartis AG 34
Panacea Biotec Limited 35
Sanofi 36
Sanofi Pasteur SA 37
Serum Institute of India Limited 38
Sinovac Biotech Ltd. 39
Synthetic Biologics, Inc. 40
Takeda Pharmaceutical Company Limited 41
Zydus Cadila Healthcare Limited 42
Pertussis - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
diphtheria + pertussis + tetanus vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + pertussis + tetanus vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
diphtheria + tetanus+ pertussis vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
diptheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DTaP Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-3111A - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pertussis (acellular) vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pertussis (acellular) vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pertussis (whole-cell) vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pertussis + hepatitis B vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pertussis vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pertussis vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pertussis vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pertussis vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pertussis vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Recombinant BCG - Pertussis Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SYN-005 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TAK-361S - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VN-0103 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Pertussis - Recent Pipeline Updates 86
Pertussis - Dormant Projects 88
Pertussis - Product Development Milestones 90
Featured News & Press Releases 90
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 90
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 90
Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 91
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 92
Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 92
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 93
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 94
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 95
Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 96
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 96
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Tables
Number of Products under Development for Pertussis, H1 2015 11
Number of Products under Development for Pertussis - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Comparative Analysis by Unknown Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Pertussis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 24
Pertussis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 25
Pertussis - Pipeline by Bharat Biotech International Limited, H1 2015 26
Pertussis - Pipeline by Biological E. Limited, H1 2015 27
Pertussis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 28
Pertussis - Pipeline by DBV Technologies S.A., H1 2015 29
Pertussis - Pipeline by Green Cross Corporation, H1 2015 30
Pertussis - Pipeline by Indian Immunologicals Limited, H1 2015 31
Pertussis - Pipeline by LG Life Sciences, Ltd., H1 2015 32
Pertussis - Pipeline by NanoBio Corporation, H1 2015 33
Pertussis - Pipeline by Novartis AG, H1 2015 34
Pertussis - Pipeline by Panacea Biotec Limited, H1 2015 35
Pertussis - Pipeline by Sanofi, H1 2015 36
Pertussis - Pipeline by Sanofi Pasteur SA, H1 2015 37
Pertussis - Pipeline by Serum Institute of India Limited, H1 2015 38
Pertussis - Pipeline by Sinovac Biotech Ltd., H1 2015 39
Pertussis - Pipeline by Synthetic Biologics, Inc., H1 2015 40
Pertussis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 41
Pertussis - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 42
Assessment by Monotherapy Products, H1 2015 43
Assessment by Combination Products, H1 2015 44
Number of Products by Stage and Target, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Pertussis Therapeutics - Recent Pipeline Updates, H1 2015 86
Pertussis - Dormant Projects, H1 2015 88
Pertussis - Dormant Projects (Contd..1), H1 2015 89